Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Regeneron Pharmaceuticals, which garnered attention in 2020 when President Donald Trump touted the company's experimental COVID-19 vaccine as a "cure," said Monday, May 19, that it will buy ...

Genetic testing firm 23andMe is set to be acquired by drug company Regeneron Pharmaceuticals following its bankruptcy in March, the companies announced on Monday, May 19. Regeneron purchased the ...

She regularly appears on CBS News 24/7 to discuss her reporting. Regeneron has agreed to buy 23andMe, the once buzzy genetic testing company, out of bankruptcy for $256 million under a court ...

In a deal raising significant privacy concerns, biotechnology giant Regeneron Pharmaceuticals announced Monday it is acquiring embattled consumer genetics company 23andMe out of bankruptcy for $ ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies insisted the sensitive genetic data provided to 23andMe by 15 million ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...

Regeneron Pharmaceuticals, a biotechnology company with a long history of large-scale genetics research, plans to buy DNA testing firm 23andMe out of bankruptcy, announcing Monday it was named the ...

Regeneron to acquire 23andMe’s genome services and Biobank for $256 million. Deal excludes Lemonaid Health; consumer services to remain uninterrupted. Beat the market with ready-to-go trades and ...